Rosenberg Robert, Friederichs Jan, Gertler Ralf, Hoos Axel, Mueller James, Nahrig Jorg, Nekarda Hjalmar, Siewert Joerg-Ruediger
Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, Ismaningerstrasse 22, Munich, Germany.
Int J Colorectal Dis. 2004 Sep;19(5):430-7. doi: 10.1007/s00384-003-0559-z. Epub 2004 Jan 10.
The value of immunohistochemical detection of disseminated tumor cells in histopathologically tumor-free lymph nodes (pN0) of patients with colorectal cancer is still of uncertain prognostic value. We therefore evaluated the immunohistochemical detection rates and their prognostic value comparing three different monoclonal antibodies.
A total of 170 lymph nodes of 85 patients with curatively resected colorectal carcinoma at UICC stage I or II were evaluated for disseminated tumor cells. Frozen sections of each lymph node were immunohistochemically stained using three antibodies directed against CEA, CK20, and Ber-EP4. The detection rates were compared with histopathological tumor parameters and with the patient's survival. The median follow-up time was 86 months.
CEA-, CK20-, and Ber-EP4-positive disseminated tumor cells were identified microscopically in lymph nodes of 23 patients (27%), 24 patients (28%), and 23 patients (27%), respectively. In 18 patients (21%) disseminated tumor cells were found in consecutive sections and stained positive for all three monoclonal antibodies. The lymph nodes of 10 of 18 patients (56%), which developed tumor recurrence, contained CEA- and CK20-positive disseminated tumor cells. Ber-EP4-positive cells were present in lymph nodes of 9 of 18 patients (50%) with tumor recurrence. The 5-year overall survival of the 23 patients with CEA-positive disseminated tumor cells was 72% compared to 91% of the patients without immunohistochemical evidence of tumor cells (p<0.01). While the identification of CK20-positive tumor cells was also correlated significantly with a worse overall patient survival (p<0.01), the application of Ber-EP4 failed to reach significance (p=0.057). Multivariate analysis identified the tumor site (colon versus rectal cancer) (p<0.006) and the presence of CEA-positive disseminated tumor cells (p<0.03) as independent prognostic factors.
In colorectal carcinoma, the immunohistochemical detection of disseminated tumor cells in histopathologically pN0 peritumoral lymph nodes allows the identification of a subgroup with a significantly worse prognosis. Nevertheless, the prognostic value of immunohistochemically detected disseminated tumor cells remains controversial due to the nonuniform data in the literature.
在结直肠癌患者组织病理学检查无肿瘤的淋巴结(pN0)中,免疫组化检测播散性肿瘤细胞的价值,其预后价值仍不确定。因此,我们比较了三种不同单克隆抗体的免疫组化检测率及其预后价值。
对85例国际抗癌联盟(UICC)I期或II期接受根治性切除的结直肠癌患者的170个淋巴结进行播散性肿瘤细胞评估。每个淋巴结的冰冻切片用三种针对癌胚抗原(CEA)、细胞角蛋白20(CK20)和Ber-EP4的抗体进行免疫组化染色。将检测率与组织病理学肿瘤参数及患者生存率进行比较。中位随访时间为86个月。
在23例患者(27%)的淋巴结中显微镜下鉴定出CEA阳性、CK20阳性和Ber-EP4阳性的播散性肿瘤细胞,分别为24例(28%)和23例(27%)。在18例患者(21%)中,在连续切片中发现播散性肿瘤细胞,且对所有三种单克隆抗体染色均为阳性。18例发生肿瘤复发的患者中,10例(56%)的淋巴结含有CEA和CK20阳性的播散性肿瘤细胞。18例肿瘤复发患者中,9例(50%)的淋巴结存在Ber-EP4阳性细胞。23例CEA阳性播散性肿瘤细胞患者的5年总生存率为72%,而无肿瘤细胞免疫组化证据的患者为91%(p<0.01)。虽然鉴定出CK20阳性肿瘤细胞也与患者总体生存率较差显著相关(p<0.01),但应用Ber-EP4未达到显著水平(p=0.057)。多因素分析确定肿瘤部位(结肠癌与直肠癌)(p<0.006)和CEA阳性播散性肿瘤细胞的存在(p<0.03)为独立预后因素。
在结直肠癌中,对组织病理学pN0肿瘤周围淋巴结中播散性肿瘤细胞进行免疫组化检测,可识别出预后明显较差的亚组。然而,由于文献数据不统一,免疫组化检测播散性肿瘤细胞的预后价值仍存在争议。